- $53.65m
- -$46.08m
- $9.85m
- 48
- 33
- 47
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.67 | ||
| Price to Tang. Book | 0.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.84 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -70.15% | ||
| Return on Equity | -59.49% | ||
| Operating Margin | -765.18% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 6.29 | 9.85 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases. Its product candidates include KB-9558 and KB-7898. KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN, is in preclinical development for the treatment of multiple myeloma and human papillomavirus (HPV)-driven tumors. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. KB-7898 is a p300 KAT inhibitor for the treatment of Sjogren’s disease, a chronic autoimmune disease that is characterized by the production of autoantibodies, chronic inflammation and lymphocytic infiltration of the exocrine glands that lead to uncomfortable dryness symptoms, known as sicca.
Directors
- Arie Belldegrun NEC (71)
- Norbert Bischofberger PRE (65)
- Yasir Al-Wakeel CFO (39)
- Barbara Kosacz COO (63)
- Jorge DiMartino EVP (57)
- Christopher Dinsmore CSO (55)
- Roshawn Blunt DRC
- Joshua Kazam DRC (44)
- David Tanen DRC (49)
- Marianne De Backer IND (53)
- Elena Ridloff IND (41)
- Otello Stampacchia IND (51)
- Yang Taiyin IND (67)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- June 2nd, 2017
- Public Since
- October 9th, 2020
- No. of Shareholders
- 37
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 60,969,214
- Address
- 1300 S. El Camino Real, Suite 400, SAN MATEO, 94402
- Web
- https://www.kronosbio.com/
- Phone
- +1 6507815200
- Contact
- Margaux Bennett
- Auditors
- Ernst & Young LLP
Upcoming Events for KRON
Q2 2025 Kronos Bio Inc Earnings Release
Q3 2025 Kronos Bio Inc Earnings Release
Q3 2025 Kronos Bio Inc Earnings Release
Similar to KRON
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Kronos Bio share price?
As of Today at 18:22 UTC, shares in Kronos Bio are trading at $0.88. This share price information is delayed by 15 minutes.
How has the Kronos Bio share price performed this year?
Shares in Kronos Bio last closed at $0.88 and the price had moved by -14.15% over the past 365 days. In terms of relative price strength the Kronos Bio share price has underperformed the S&P500 Index by -22.37% over the past year.
What are the analyst and broker recommendations for Kronos Bio?
The overall consensus recommendation for Kronos Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Kronos Bio dividend yield?
Kronos Bio does not currently pay a dividend.
Does Kronos Bio pay a dividend?
Kronos Bio does not currently pay a dividend.
When does Kronos Bio next pay dividends?
Kronos Bio does not currently pay a dividend.
How do I buy Kronos Bio shares?
To buy shares in Kronos Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kronos Bio?
As of the previous close price of $0.88, shares in Kronos Bio had a market capitalisation of $53.65m.
Where are Kronos Bio shares listed?
Here are the trading details for Kronos Bio:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: KRON
What kind of share is Kronos Bio?
Based on an overall assessment of its quality, value and momentum Kronos Bio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kronos Bio share price forecast for 2025?
The analyst consensus target price for shares in Kronos Bio is $2.25. That is 155.68% above the last closing price of $0.88.
Analysts covering Kronos Bio currently have a consensus Earnings Per Share (EPS) forecast of -$1.30 for the next financial year.
Find out moreWhat is the trend in the Kronos Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kronos Bio. Over the past six months, its share price has underperformed the S&P500 Index by -9.29%.
As of the last closing price of $0.88, shares in Kronos Bio were trading -3.17% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kronos Bio PE Ratio?
The Kronos Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.88.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kronos Bio?
Kronos Bio's management team is headed by:
- Arie Belldegrun - NEC
- Norbert Bischofberger - PRE
- Yasir Al-Wakeel - CFO
- Barbara Kosacz - COO
- Jorge DiMartino - EVP
- Christopher Dinsmore - CSO
- Roshawn Blunt - DRC
- Joshua Kazam - DRC
- David Tanen - DRC
- Marianne De Backer - IND
- Elena Ridloff - IND
- Otello Stampacchia - IND
- Yang Taiyin - IND